Photocure partner Asieris presents Phase III subgroup analysis of Cevira (APL-1702) by age group at the 2024 CSCO Annual Meeting.

PR message

OSLO, Norway, September 30, 2024

OSLO, Norway , Sept. 30, 2024 /PRNewswire/ — Photocure ASA (OSE: PHO), a Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) announced that data from the international multicenter Phase III clinical trial for – Surgical candidate Cevira® (APL-1702) for cervical high-grade squamous intraepithelial lesion (HSIL) was published by the 27th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in the form of a poster, focusing on the analysis of different age subgroups regarding the pathological regression rate within six months and the HPV virus clearance rate.

This Phase III clinical trial is a prospective, randomized, multicenter, double-blind, placebo-controlled clinical trial that met its primary efficacy endpoint and demonstrated good safety.

Additionally, study outcomes included pathologic regression rate (defined as the percentage of patients with pathologic regression to CIN1 or normal tissue) at month 6 across age subgroups. Both ‘=20 and

Regarding the HPV clearance rate, in ‘=20 i

You can read Asieris’ full press release here:

Note to editors:

All trademarks mentioned in this notice are protected by law and are registered trademarks of Photocure ASA. This press release may contain product details and information that is invalid or the product is not available in your country. Please note that Photocure is not responsible for any access to such information that may be inconsistent with any legal process, regulation, registration or use in your country of origin.

About Cevira® Cevira® (APL-1702) is a photodynamic drug-device combination currently in development. Based on the principles of photodynamic therapy, Cevira aims to use a photosensitizer in combination with light activation to achieve a therapeutic effect in the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL) in patients 18 years of age and older, excluding carcinoma in situ . Photocure developed Cevira through Phase I and Phase II studies, and global development and commercialization rights were transferred to Asieris Meditech Co., Ltd in 2019. In November 2020, Asieris initiated a Phase III clinical trial for APL -1702 ( Cevira), which met its primary endpoint in September 2023, clinical trial number: NCT04484415. The New Drug Application for APL-1702 was accepted by the National Medical Products Administration (NMPA) in May 2024.

About Photocure ASAPhotocure: Bladder Cancer Company provides revolutionary solutions to improve the quality of life of patients with bladder cancer. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients around the world. Photocure is headquartered in Oslo, Norway and is listed on the Oslo Stock Exchange (OSE: PHO). More information can be found at www.photocure.com

About AsierisAsieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharmaceutical company specializing in the discovery, development and commercialization of innovative medicines for the treatment of genitourinary cancers and other related diseases.

For further information please contact:

Dan SchneiderPresident and CEOPhotocure ASAEmail: (email protected)

Erik DahlCFOPhotocure ASATtel: +4745055000Email: (email protected)

David Moskowitz Vice President, Investor RelationsPhotocure ASAT Tel: +1 202 280 0888 Email: (email protected)

Media and IR inquiries:

Geir BjørloCorporate Communications (Norway)Tel: +47 91540000Email: (email protected)

This information was brought to you by Cision

The following files are available for download:

Release

View original content:

SOURCE Photocuration